Cambridge Arts has released three new open datasets on the city's public art, offering insights into artworks, conservation ...

Amid recent government crackdowns on foreign-owned services like WhatsApp and YouTube, people entering Russia will now need ...

Masterworks offers average investors a chance to buy individual shares in paintings often only owned by the rich, but critics ...

An analysis of foodborne outbreak data collection in Austria has found issues with completeness and consistency. A report published by the European Food Safety Authority (EFSA) shared results of a ...

Hello and welcome to the newsletter, a grab bag of daily content from the Odd Lots universe. Sometimes it's us, Joe Weisenthal and Tracy Alloway, bringing you our thoughts on the most recent ...

SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today ...

TOKYO/WASHINGTON :The U.S. government shutdown that has turned off the official flow of data could begin clouding the view for policymakers in Japan and other countries where insight into the fortunes ...

First-party data is, as the kids say, having a moment. The concept resurfaced in the public consciousness when Google postponed its anticipated phase-out of third-party cookies on Chrome until 2024.

Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the ...

The Department of Labor is initiating an investigation into how the Bureau of Labor Statistics collects and reports “closely watched economic data,” according to a letter the department’s Assistant ...

FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...